IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97, and §1.98



PTO-1449 FORM

SHEET 1 OF 4

ATTORNEY DOCKET NO.:	SERIAL NO.:	
R0368-04000	10/716,329	

APPLICANTS: EXAMINER:

Burbank et al. Not yet assigned

FILING DATE: GROUP ART UNIT:

November 18, 2003 3731

U.S. PATENT DOCUMENTS

			U.S. PATE	NT DOCUMENTS		
† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
	*A1	3,209,753	10/65	Hawkins et al.		
	*A2	3,411,505	11/68	Nobis		
	*A3	4,292,960	10/81	Paglione		
	*A4	4,428,374	1/84	Auburn		
	*A5	4,428,379	1/84	Robbins et al.		
	*A6	4,509,528	4/85	Sahota		
	*A7	4,650,466	1/87	Luther		
	*A8	4,757,823	7/88	Hofmeister et al.		
	*A9	4,991,588	2/91	Pflueger et al.		ļ
	*A10	4,994,069	2/91	Ritchart et al.		
	*A11	5,037,433	8/91	Wilk et al.		
	*A12	5,081,997	1/92	Bosley, Jr. et al.		
	*A13	5,108,408	4/92	Lally		
	*A14	5,201,314	4/93	Bosley et al.		
	*A15	5,226,911	7/93	Chee et al.		
	A16	5,261,409	11/93	Dardel		
	*A17	5,275,166	1/94	Vaitenkunas et al.		
	*A18	5,289,831	3/94	Bosley		
	*A19	5,336,229	8/94	Noda, Wayne A.	100	
	*A20	5,336,231	8/94	Adair		
	*A21	5,383,922	1/95	Zipes et al.		
	*A22	5,456,693	10/95	Conston et al.		
	*A23	5,458,596	10/95	Lax et al.		
	*A24	5,488,958	2/96	Topel et al.		
	*A25	5,496,331	3/96	Xu et al.		
	*A26	5,507,744	4/96	Tay et al.		
	*A27	5,542,944	8/96	Bhatta		
	*A28	5,549,624	8/96	Mirigian et al.		
	*A29	5,549,824	7/96	Trumpf et al.		
	*A30	5,556,396	9/96	Cohen et al.		
	*A31	5,562,680	10/96	Hasson		
	*A32	5,570,692	11/96	Morinaga		
	*A33	5,588,960	12/96	Edwards et al.		
	*A34	5,614,204	1/97	Cochrum		
	*A35	5,658,299	8/97	Hart		
	A36	5,662,676	9/97	Koninckx		
	*A37	5,662,680	9/97	Desai		
	*A38	5,665,096	9/97	Yoon		
	*A39	5,672,153	9/97	Lax et al.		
	*A40	5,672,172	9/97	Zupkas		
	*A41	5,691,314	11/97	Hodgen		
	*A42	5,697,937	12/97	Toma		

SERIAL NO .: IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO .: R0368-04000 10/716,329 INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, and §1.98 APPLICANTS: EXAMINER: **PTO-1449 FORM** Burbank et al. Not yet assigned GROUP ART UNIT: FILING DATE: SHEET 2 OF 4 3731 November 18, 2003 U.S. PATENT DOCUMENTS CONT'D U.S. CLASS/ FILING DATE †EX'R *REF. # PATENT NUMBER DATE (MO/YR) NAME **SUBCLASS** (If appropriate) INITIAL Palti 5,697,942 12/97 *A43 12/97 Kaji *A45 5,702,407 *A46 5,713,896 2/98 Nardella 2/98 Stern et al. *A47 5,713,942 2/98 *A48 5,715,832 Koblish et al. 5,716,389 2/98 Walinsky et al. *A49 *A50 5,720,743 2/98 Bischof et al. 5/98 Prestel et al. *A51 5,746,750 *A52 5,749,879 5/98 Middleman et al. 6/98 Hovns *A53 5,759,154 *A54 5,766,135 6/98 Terwilliger 7/98 Mersch *A55 5,776,129 Rosenberg *A56 5,797,397 8/98 9/98 Edwards et al. *A57 5,800,378 Vesely 10/98 *A58 5,817,022 *A59 5,836,906 11/98 **Edwards** 11/98 Takeuchi *A60 5,840,033 *A61 5,895,386 4/99 Odell et al. 4/99 *A62 5,895,395 Yeung 5/99 Friemel et al. *A63 5.899,861 *A64 5,904,651 5/99 Swanson et al. *A65 5,910,484 6/99 Haupert, Jr. 6/99 Mochizuki et al. *A66 5,911,691 7/99 Sarkis et al. *A67 5,921,933 8/99 Cermak *A68 5,941,889 11/99 *A69 5,979,453 Savage et al. 11/99 *A70 5,980,534 Gimpelson *A71 6,013,088 1/00 Karavidas 1/00 Greff et al. *A72 6,015,541 2/00 Gronningsaeter et al. *A73 6,019,724 3/00 *A74 6,032,673 Savage et al. 3/00 Farley et al. *A75 6.033.398 3/00 Peeters et al. *A76 6,034,477 *A77 6,035,238 3/00 Ingle et al. *A78 3/00 Seward et al. 6,039,693 *A79 6.045,508 4/00 Hossack et al. 5/00 *A80 6,066,139 Ryan et al. *A81 6.077,257 6/00 Edwards et al. 8/00 Kortenbach et al. *A82 6.096.051 *A83 6,106,473 8/00 Violante et al. *A84 6,186,947 2/01 Ouchi

IN THE	UNITED S	TATES PATENT AND 1	RADEMARK OFFICE	ATTORNEY DOCKET NO.:	SERIAL NO.:	
INF		ON DISCLOSURI 37 CFR §1.56, §1.97		R0368-04000	10/71	6,329
				APPLICANTS:	EXAMINER:	
PTO-1449 FORM			Burbank et al.	Not yet	Not yet assigned	
					- Not yet	assigned
		OUEET 2 OF 4		FILING DATE:	GROUP ART UN	IT:
		SHEET 3 OF 4		November 18, 2003	37	731
	<u> </u>		U.S. PATENT DO	CUMENTS CONT'D	-	
† EX'R INITIAL	*REF.#	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate
	*A85	6,210,330	4/01	Tepper		, ,,,,, <u>,</u>
_	*A86	6,231,515	5/01	Moore et al.		
···	*A87	6,254,601	7/01	Burbank et al.		
	*A88	6,261,234	7/01	Lin		
	*A89	6,280,441	8/01	Ryan		
	*A90	6,368,340	4/02	Malecki et al.		
	*A91	6,425,867	7/02	Vaezy et al.		
			FOREIGN PATE	NT DOCUMENTS		
† EX'R INITIAL	*REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)
	B1	SU 1 072 859 a	2/84	SOVIET UNION		
	*B2	EP 0 472 368	2/92	EPO		
	*B3	EP 0 598 579	5/94	EPO		
	*B4	WO 95/02370	1/95	PCT		
	*B5	WO 95/02371	1/95	PCT		
	B6	WO 96/05776	2/96	WIPO		
	*B7	WO 96/10365	4/96	WIPO		
	B8	GB 2 302 025	1/97	GREAT BRITAIN	 	
	*B9	GB 2 311 468 A	1/97	GREAT BRITAIN		
	*B10	DE 195 28 440 A	2/97	GERMANY		
	*B11	WO 97/27897	8/97	WIPO		
	*B12	WO 97/47246	12/97	WIPO		
	*B13	WO 98/19713	5/98	PCT		
,	*B14	WO 99/00057	1/99	WIPO		
	*B15	EP 1 072 282	1/01	EPO		
	*B16	DE 200 22 012 U1	5/01	GERMANY		
	*B17	WO 02/39904 A1	5/02	WIPO		<u> </u>
			OTHER DO	OCUMENTS		1
† EX'R INITIAL	*REF.#	Document Description (including Author, Title, Date, Pertinent Pages, Etc.)				
	*C1			w-Up of Transcatheter Emboliza nvestigative Radiology, May-Jur		
	*C2		D., "Treatment of intra c. 89(6):825-827 (July	octable menorrhagia by bilateral 15, 1964).	uterine vessel, In	terruption",
	*C3	Brigato, G. et al., "A Ginecologica 50(7-8		ntal Method in Severe Postpartu	m Hemorrhages'	', Minerva

SERIAL NO.: ATTORNEY DOCKET NO .: IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10/716,329 R0368-04000 INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, and §1.98 **EXAMINER:** APPLICANTS: **PTO-1449 FORM** Not yet assigned Burbank et al. GROUP ART UNIT: FILING DATE: SHEET 4 OF 4 3731 November 18, 2003 OTHER DOCUMENTS CONT'D

†EX'R INITIAL	*REF. #	Document Description (including Author, Title, Date, Pertinent Pages, Etc.)		
	*C4	Brohim, Robert M. et al., "Development of Independent Vessel Security After Ligation With Absorbable Sutures or Clips", <i>The American Journal of Surgery</i> , Mar. 1993, Vol. 165, pp. 345-348.		
	*C5	Burbank, Fred et al., "Uterine Artery Occlusion by Embolization or Surgery for the Treatment of Fibroids: A Unifying Hypothesis-Transient Uterine Ischemia", <i>The Journal of the American Association of Gynecologic Laparoscopists</i> , November 2000, Vol. 7, No. 7 Supplemental, pp. S3-S49.		
	*C6	Fuchs, Karl, "Afibrinogenemia Treated by Ligation of Uterine Arteries", Gynacologic 148:407-411 (1959).		
	*C7	Garza Leal, J. et al., "Myoma Treatment by Transient Uterine Ischemia", <i>The Journal of the American Association of Gynecologic Laparoscopists</i> 7(3):S31 (August 2000).		
	*C8	Hay, D.L. et al., "Hemostasis in Blood Vessels After Ligation", <i>Am. J. Obstet. Gynecol.</i> , March 1989, 160:3, pp. 737-739.		
	*C9	Hunerbein, M. et al., "Endoscopic Ultrasound-Guided Real Time Biopsy of Peri-Intestinal Tumors", Surgical Technology International VII, 1998, pp. 91-95.		
	*C10	O'Leary, James A., M.D., "Uterine Artery Ligation in the Control of Postcesarean Hemorrhage", <i>The Journal of Reproductive Medicine, Inc.</i> , 40(3):189-193 (March 1995).		
	*C11	O'Leary, James L., M.D. et al., "Uterine artery ligation in the control of intractable postpartum hemorrhage", Am. J. Obst. & Gynec. 94(7):920-924 (April 1, 1966).		
	*C12	Ravina, J.H. et al., "Arterial Embolisation to Treat Uterine Myomata", <i>The Lancet</i> , Sept. 9, 1995, Vol. 346, No. 8976, pp. 671-672.		
	*C13	Schaefer, C.J. et al., "Absorbable Ligating Clips", Surg. Gynecol. Obstet., 1982, 154:513-516.		
	*C14	"Mick 200-TP Applicator Package", Mick Radio-Nuclear Instruments, Inc., advertisement.		
	*C15	"Multiplanar Biopsy Transverse Scan", Bruel & Kjaer Medical Systems, Inc., advertisement.		
	*C16	"Seeding Device – Proscan Urologic Ultrasound Imaging System", Teknar, advertisement.		
	*C17	"Sonopsy Ultrasound Guided Breast Biopsy, NeoVision, advertisement.		
	*C18	"Transrectal Biopsy of the Prostrate Gland", Bruel & Kjaer Medical Systems, Inc., advertisement.		
XAMINE	R'S SIGNAT	TURE DATE CONSIDERED		

† EXAMINER:

Initial if reference is considered, whether or not citation is in conformance with MPEP 609.

Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).